These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25263480)

  • 1. Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
    Huber K; Feuchtinger A; Borgmann DM; Li Z; Aichler M; Hauck SM; Zitzelsberger H; Schwaiger M; Keller U; Walch A
    Anal Chem; 2014 Nov; 86(21):10568-75. PubMed ID: 25263480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging.
    Tsubata Y; Hayashi M; Tanino R; Aikawa H; Ohuchi M; Tamura K; Fujiwara Y; Isobe T; Hamada A
    Sci Rep; 2017 Oct; 7(1):12622. PubMed ID: 28974758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
    Végvári Á; Fehniger TE; Rezeli M; Laurell T; Döme B; Jansson B; Welinder C; Marko-Varga G
    J Proteome Res; 2013 Dec; 12(12):5626-33. PubMed ID: 24134601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry.
    Signor L; Varesio E; Staack RF; Starke V; Richter WF; Hopfgartner G
    J Mass Spectrom; 2007 Jul; 42(7):900-9. PubMed ID: 17534860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer.
    Grüner BM; Winkelmann I; Feuchtinger A; Sun N; Balluff B; Teichmann N; Herner A; Kalideris E; Steiger K; Braren R; Aichler M; Esposito I; Schmid RM; Walch A; Siveke JT
    Mol Cancer Ther; 2016 May; 15(5):1145-52. PubMed ID: 26823494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
    Poot AJ; van der Wildt B; Stigter-van Walsum M; Rongen M; Schuit RC; Hendrikse NH; Eriksson J; van Dongen GA; Windhorst AD
    Nucl Med Biol; 2013 May; 40(4):488-97. PubMed ID: 23522977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI.
    Buck A; Halbritter S; Späth C; Feuchtinger A; Aichler M; Zitzelsberger H; Janssen KP; Walch A
    Anal Bioanal Chem; 2015 Mar; 407(8):2107-16. PubMed ID: 25311193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
    Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
    Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis.
    Swales JG; Tucker JW; Strittmatter N; Nilsson A; Cobice D; Clench MR; Mackay CL; Andren PE; Takáts Z; Webborn PJ; Goodwin RJ
    Anal Chem; 2014 Aug; 86(16):8473-80. PubMed ID: 25084360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.
    Huber K; Aichler M; Sun N; Buck A; Li Z; Fernandez IE; Hauck SM; Zitzelsberger H; Eickelberg O; Janssen KP; Keller U; Walch A
    Histochem Cell Biol; 2014 Oct; 142(4):361-71. PubMed ID: 24824474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues.
    Drexler DM; Garrett TJ; Cantone JL; Diters RW; Mitroka JG; Prieto Conaway MC; Adams SP; Yost RA; Sanders M
    J Pharmacol Toxicol Methods; 2007; 55(3):279-88. PubMed ID: 17222568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
    Liu X; Ide JL; Norton I; Marchionni MA; Ebling MC; Wang LY; Davis E; Sauvageot CM; Kesari S; Kellersberger KA; Easterling ML; Santagata S; Stuart DD; Alberta J; Agar JN; Stiles CD; Agar NY
    Sci Rep; 2013 Oct; 3():2859. PubMed ID: 24091529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of quantitative whole-body autoradiography (QWBA) and imaging mass spectrometry (IMS) by matrix-assisted laser desorption/ionization (MALDI) in the assessment of ocular distribution of drugs.
    Drexler DM; Tannehill-Gregg SH; Wang L; Brock BJ
    J Pharmacol Toxicol Methods; 2011; 63(2):205-8. PubMed ID: 21040797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA.
    Batubara A; Carolan VA; Loadman PM; Sutton C; Shnyder SD; Clench MR
    Rapid Commun Mass Spectrom; 2015 Jul; 29(14):1288-96. PubMed ID: 26405790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.
    Ryu S; Ohuchi M; Yagishita S; Shimoi T; Yonemori K; Tamura K; Fujiwara Y; Hamada A
    Sci Rep; 2020 Sep; 10(1):15535. PubMed ID: 32968211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug compound characterization by mass spectrometry imaging in cancer tissue.
    Kwon HJ; Kim Y; Sugihara Y; Baldetorp B; Welinder C; Watanabe K; Nishimura T; Malm J; Török S; Döme B; Végvári Á; Gustavsson L; Fehniger TE; Marko-Varga G
    Arch Pharm Res; 2015 Sep; 38(9):1718-27. PubMed ID: 26198812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
    Muselaers CH; Stillebroer AB; Desar IM; Boers-Sonderen MJ; van Herpen CM; de Weijert MC; Langenhuijsen JF; Oosterwijk E; Leenders WP; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2014 Feb; 55(2):242-7. PubMed ID: 24396030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
    Tlemsani C; Huillard O; Arrondeau J; Boudou-Rouquette P; Cessot A; Blanchet B; Thomas-Schoemann A; Coriat R; Durand JP; Giroux J; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):785-94. PubMed ID: 25809423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.